- Previous Close
30.00 - Open
31.00 - Bid 31.00 x --
- Ask 32.00 x --
- Day's Range
30.00 - 33.00 - 52 Week Range
28.00 - 57.00 - Volume
1,825,400 - Avg. Volume
818,900 - Market Cap (intraday)
8.2B - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-5.04 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions comprise personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. The company serves medical institutions, research institutions, and biopharmaceutical companies. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.
www.medinet-inc.co.jpRecent News: 2370.T
View MorePerformance Overview: 2370.T
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2370.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2370.T
View MoreValuation Measures
Market Cap
7.94B
Enterprise Value
3.29B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.33
Price/Book (mrq)
1.53
Enterprise Value/Revenue
4.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.09%
Return on Equity (ttm)
-69.34%
Revenue (ttm)
998M
Net Income Avi to Common (ttm)
-3.05B
Diluted EPS (ttm)
-5.04
Balance Sheet and Cash Flow
Total Cash (mrq)
2.2B
Total Debt/Equity (mrq)
2.17%
Levered Free Cash Flow (ttm)
-1.55B